Welcome to the ATTD 2022 Interactive Program
The conference will officially run on Central European Summer Time (UTC+2) - Barcelona Time
To convert the conference times to your local time Click Here
Session Description:
This engaging symposium, sponsored by Lilly, will explore new clinical frontiers in the management of type 2 diabetes (T2D). Join our panel of internationally renowned experts as they discuss important and clinically relevant topics such as:
• The need for a holistic approach in treating people with T2D
• Benefits of early intervention and tighter control in the management of diabetes
• How this clinical evidence can impact T2D care and improve patient outcomes
Chaired by Christophe de Block (Belgium), the symposium will consist of two cutting-edge scientific presentations, followed by an open and interactive discussion session. Expert speakers include Stefano Del Prato (Italy) and Tadej Battelino (Slovenia). Coffee and breakfast style refreshments will be served.
Session Description:
This practical session chaired by Prof. Ohad Cohen, Medical Director of Medtronic, will focus on how to onboard people with type 1 diabetes on the MiniMed™ 780G system, aiming to achieve the highest possible glycemic control while minimizing the demands on users and caretakers.
Dr. Pilar Beato-Víbora from Badajoz University Hospital, Spain, will share her experience, in onboarding adult individuals from either MDI therapy or SAP therapy to the MiniMed™ 780G system. She will present cases from the prospective research ongoing in her practice.,
Dr. Henk-Jan Aanstoot, will address the onboarding and follow up of pediatric individuals, leveraging on cases from the Diabeter centre, the Netherlands. The participants will be able to comment and share their experiences and insights.
Session Description:
This symposium will focus on the variety of real-world retrospective data and correlational outcomes seen with the use of Dexcom G6 and Dexcom ONE around the world. Dexcom’s Data Science Team will share the global use of various features of the Dexcom CGM products, including Dexcom CLARITY, how alerts are used and customized by Dexcom users and trend of glycemic control with the customization of Dexcom alerts. Finally, this symposium will review the ever-growing global Dexcom digital partners and the new and exciting RWE on the combined use of Welldoc BlueStar and Dexcom G6 in a population health pilot program.
Session Description:
During this symposium we will discuss the potential for digital health, focusing on smart pen technology, in helping overcome challenges for patients and HCPs in achieving glycaemic control. The Chair, Søren Smed Østergaard (Novo Nordisk), will lead us through an exciting programme of scientific presentations followed by expert panel discussions, including patient insights, to help frame the scientific data in a real-world context with the opportunity for questions from the audience. Professor Richard Bergenstal will overview barriers to glycaemic control and introduce some of the potential digital health solutions such as smart pen technology followed by a panel discussion. After, Professor Bergenstal will continue by examining the clinical evidence for the use of smart pens focusing on data on time-in-range and insulin treatment adherence before the second panel discussion looking at the realities of managing diabetes with aid of smart pen technology. Finally, Dr Peter Adolfsson will look into the future to examine how digital health and the increased availability of patient data could help drive a more personalized approach to care. The symposium will close with a panel discussion reflecting on the future of digital health and the opportunities to help improve outcomes for people with diabetes. During the panel discussions we will also be joined by Dr Markus Menzen to provide his clinical insights on digital health.